

Various cardiovascular diseases and prevention

“Many pre- and clinical studies confirmed the important role of elevated plasma Lp(a) in increasing risk of ASCVD [atherosclerotic cardiovascular disease], which is independent of the LDL-C [low-density lipoprotein cholesterol] effects. This makes hyperlipoproteinemia (a) an optimal therapeutic target in ASCVD prevention.” Zlatko Fras, from Slovenia, points out that Lp(a) has recently become a much more widely considered risk factor.

“Aspirin use in primary cardiovascular prevention” is still a challenging topic in medicine. Alberto Aimo and Raffaele De Caterina, from Italy, reviewed this issue, looking at the latest data and guideline recommendations. It is a very comprehensive and useful review.

Fabry disease is a rare and progressive disease with potentially life-threatening complications. Barman et al., from Turkey, will increase awareness with their report, “Ratio of Fabry disease in patients with idiopathic left ventricular hypertrophy: A single-center study.”

Kim et al., from South Korea, followed patients with acute myocardial infarction with dyslipidemia for two years after successful stent implantation. They compared the clinical outcomes of patients using angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor blocker therapies. This topic merits discussion.

Bozkaya et al., from Turkey, screened and evaluated newly diagnosed cardiovascular disease in first trimester, asymptomatic pregnant women at a tertiary antenatal care center. This is a reminder that clinicians must keep cardiovascular disease in mind when treating pregnant women.

Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the leading causes of pulmonary hypertension (PH). Küçükoğlu et al., from Turkey, investigated the baseline characteristics and outcomes of CTEPH patients (operated and non-operated patients) who were followed up at a PH outpatient clinic for 10 years. This report is a valuable contribution to the literature on this very difficult disease.

As always, we also offer interesting case reports, e-page originals, and more.

I hope this issue will be of interest of our readers.

Prof. Dr. Çetin Erol
Editor-in-Chief
Ankara-Turkey

Address for Correspondence: Prof. Dr. Çetin Erol, Ankara Üniversitesi Tıp Fakültesi, İbn-i Sina Hastanesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye

Phone: +90 312 310 33 33 /27 79 E-mail: ctnerol@yahoo.com

©Copyright 2020 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com
DOI:10.14744/AnatolJCardiol.2020.2

